Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

17%

5 trials in Phase 3/4

Results Transparency

8%

1 of 12 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (10)
P 2 (6)
P 3 (5)

Trial Status

Completed12
Recruiting11
Not Yet Recruiting3
Unknown3
Suspended1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT07455383Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07365566Not ApplicableRecruiting

Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder

NCT06752668Phase 2RecruitingPrimary

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07540897Phase 3Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

NCT07096674Phase 2RecruitingPrimary

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT06251063Not ApplicableCompletedPrimary

Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence

NCT06531876CompletedPrimary

Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy

NCT06383806Not ApplicableNot Yet Recruiting

Decreasing Nightmares in Adults With Narcolepsy

NCT07299097RecruitingPrimary

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

NCT05816382Phase 2RecruitingPrimary

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT06767683Phase 2RecruitingPrimary

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06292598RecruitingPrimary

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

NCT06358950Phase 2CompletedPrimary

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

NCT06505031Phase 3CompletedPrimary

A Study of TAK-861 in People With Narcolepsy Type 1

NCT06470828Phase 3CompletedPrimary

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

NCT06457945Not ApplicableRecruitingPrimary

Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

NCT05687903Phase 2CompletedPrimary

A Study of TAK-861 in Participants With Narcolepsy Type 1

NCT06484348Not ApplicableRecruitingPrimary

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

NCT06336057RecruitingPrimary

Mentalizating in Adults Suffering from Narcolepsy Type 1.

NCT06241911Not ApplicableCompletedPrimary

Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1

Scroll to load more

Research Network

Activity Timeline